Company intelligence / Profile preview

Metabasis Therapeutics

San Diego, California, United Statesmbasis.com ↗

Ownership: Private
Development stage: Other

Overview

Metabasis Therapeutics developed a broad pipeline targeting metabolic and liver diseases using proprietary technologies such as HepDirect® for targeted drug delivery to the liver. Its lead programs included a TR Beta agonist for hyperlipidemia, PTP‑1B inhibitors for diabetes, and adenosine regulating agents. Several candidates reached clinical trials; one program licensed out was in Phase III at the time of acquisition.

Therapeutic areas: Metabolic DisordersCardiovascularGastroenterology
Modalities: Small moleculesProdrugs (notably via HepDirect® technology)NuMimetic™ technology-based compounds
Industry: Biotech

Partnerships

Roche partnership acquired by Ligand through this dealPeriCor Therapeutics sublicensed rights from MetabasisMerck & Co. (via PeriCor Therapeutics)

Beyond the preview

Go deeper on Metabasis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabasis Therapeutics.